During the study, participants will follow a specific course involving regular injections. Researchers will look at several factors, such as the amount of cannabis used and changes in biological markers like THC levels in the blood and urine. THC is the main substance in cannabis that causes its effects. Other aspects being monitored include sleep quality, mood, and physical measurements such as body weight and blood pressure.

During the trial, individuals will undergo a process involving a single dose of the medication followed by six sessions of psychological support. The psychological support involves talking with trained professionals to assist with the treatment process. The study will monitor various aspects of the experience, including changes in mood, anxiety, and the ability to function in daily life, as well as the frequency of drug use. Safety will also be monitored through regular checks of heart health, such as an ECG, which is a test that records the electrical activity of the heart, and through laboratory tests to check blood and organ function.

Participants in the study will receive either N-acetylcysteine or a placebo, which looks like the medication but does not contain the active substance. The study will last for a short period, and participants will be monitored to see how the treatment affects their cannabis dependence. The goal is to evaluate the working mechanisms of N-acetylcysteine in helping individuals reduce their dependence on cannabis.

Throughout the study, participants will take the medication in the form of an oral solution, which means it is taken by mouth. The study will help researchers understand if N-acetylcysteine can be an effective treatment for those struggling with cannabis dependence, potentially offering a new way to support individuals in overcoming this condition.

Participants in the study will receive the treatment over a period of up to 12 weeks. The study aims to find out if the treatment can be successfully integrated into regular medical practice and if it is accepted by both patients and healthcare staff. It will also look at whether the treatment can help reduce the use of illegal opioids or other opioid medications that are meant to be taken by mouth. Additionally, the study will assess if the treatment can improve the overall health and social situation of the participants, and if it can help them stay in treatment longer.

The trial will also monitor the safety of the treatment and its impact on reducing the use of other drugs. By the end of the study, researchers hope to gather information on how well the treatment works and whether it can be a viable option for people struggling with opioid dependence. The study is being conducted in Vienna and is expected to conclude by the end of 2025.

Participants in the study will receive either the Dexamphetamine sulfate/piracetam tablets or a placebo for a period of 24 weeks. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. The study will monitor the number of days participants abstain from cocaine use and assess their overall health status, including physical, mental, and social well-being.

The trial will also track the safety of the treatment by checking vital signs such as heart rate and blood pressure, as well as conducting other health assessments. The goal is to determine if the treatment can help reduce cocaine use and improve health outcomes for those with both cocaine and opioid use disorders. Participants will be required to visit the treatment center twice a week and cooperate with study assessments and procedures throughout the trial period.

The purpose of the study is to assess whether baclofen can aid in reducing the amount of benzodiazepines that patients take. Participants in the study will be randomly assigned to receive either baclofen or a placebo. The study will last for several weeks, during which time participants will gradually reduce their benzodiazepine intake under medical supervision. The study will monitor the total benzodiazepine consumption before and after the treatment period to evaluate the effectiveness of baclofen.

Throughout the study, researchers will also keep track of any side effects or adverse events that participants may experience. Additionally, the study will assess other factors such as anxiety levels, depression symptoms, sleep quality, and overall quality of life. The goal is to determine if baclofen can be a helpful tool in managing benzodiazepine dependence and improving the well-being of patients with this condition.

The purpose of this study is to evaluate whether maintaining patients on a stable dose of diazepam or oxazepam for 24 weeks works better than gradually reducing the dose over 20 weeks. The main focus is on measuring how these different approaches affect the use of unauthorized benzodiazepines. The medications will be given as tablets that are taken by mouth.

During the study, participants will be monitored for their mental health symptoms, reaction time, quality of life, and overall satisfaction with the treatment. The study will also track the use of other substances, any violent behavior, and safety-related events. Regular urine tests will be conducted to measure the presence of unauthorized substances. The total duration of treatment in the study is 24 weeks.